Market Place
Sourcing Support
Fresh Tracks Therapeutics Files Petition Seeking Appointment Of Custodian
17 Jun 2024 //
GLOBENEWSWIRE
Fresh Tracks Urges Stockholders to Vote at the Special Meeting on February 15th
14 Feb 2024 //
GLOBENEWSWIRE
Fresh Tracks Announces Plan to Hold New Special Meeting of Stockholders
27 Dec 2023 //
GLOBENEWSWIRE
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market
19 Dec 2023 //
GLOBENEWSWIRE
Fresh Tracks Announces Common Stock will be Suspended from Trading on Nasdaq
18 Dec 2023 //
GLOBENEWSWIRE
Fresh Tracks Announces Third Adjournment of Special Meeting of Stockholders
15 Dec 2023 //
GLOBENEWSWIRE
Fresh Tracks Announces Second Adjournment of Special Meeting of Stockholders
01 Dec 2023 //
GLOBENEWSWIRE
Fresh Tracks Announces Adjournment of Special Meeting of Stockholders
17 Nov 2023 //
GLOBENEWSWIRE
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Fresh Tracks to dissolve after hunt for buyer comes up empty
19 Sep 2023 //
FIERCE BIOTECH
Fresh Tracks Announces Board Approval of Plan of Liquidation and Dissolution
19 Sep 2023 //
GLOBENEWSWIRE
Fresh Tracks pauses R&D run as hunt for buyer continues
14 Aug 2023 //
FIERCE BIOTECH
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments
21 Jul 2023 //
GLOBENEWSWIRE
Fresh Tracks Therapeutics Reports 1Q 2023FYR &Provides Corporate Update
10 May 2023 //
GLOBENEWSWIRE
Fresh Tracks Therapeutics Reports 4Q and Full Reports Full 2022 FYR
30 Mar 2023 //
GLOBENEWSWIRE
Fresh Tracks considers options to stay afloat and develop autoimmune candidates
09 Mar 2023 //
ENDPTS
Fresh Tracks mulls sale to continue autoimmune pipeline
08 Mar 2023 //
FIERCE BIOTECH
Fresh Tracks Therapeutics Announces Positive Results from PI of Oral DYRK1A
07 Mar 2023 //
GLOBENEWSWIRE
Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer
27 Jan 2023 //
GLOBENEWSWIRE
Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02
11 Jan 2023 //
GLOBENEWSWIRE
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics
07 Sep 2022 //
GLOBENEWSWIRE
Brickell Biotech deviates from old plans, rebrands for fresh start
07 Sep 2022 //
FIERCEBIOTECH
Brickell Biotech Reports Q2 2022 Rusult and Provides Corporate Update
11 Aug 2022 //
GLOBENEWSWIRE
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
20 Jul 2022 //
GLOBENEWSWIRE
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
06 Jul 2022 //
GLOBENEWSWIRE
Brickell Biotech Announces 1-For-45 Reverse Stock Split
02 Jul 2022 //
GLOBENEWSWIRE
Brickell Biotech receives delisting notice from Nasdaq
16 Jun 2022 //
DAILYCAMERA
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
19 May 2022 //
GLOBENEWSWIRE
Brickell Biotech Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Brickell Biotech to Report First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Botanix Pharmaceuticals in Acquisition of Sofpironium Bromide
04 May 2022 //
TROUTMAN
Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharma
03 May 2022 //
GLOBENEWSWIRE
Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders
03 May 2022 //
GLOBENEWSWIRE
Brickell Biotech Reports Q4 and FY 2021Â Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
Brickell`s Oral Presentation of US PIII Cardigan I and Cardigan II Study Results
10 Mar 2022 //
GLOBENEWSWIRE
Brickell Biotech to Report Q4 and FY 2021 Financial Results
08 Mar 2022 //
GLOBENEWSWIRE
Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock
27 Oct 2021 //
GLOBENEWSWIRE
Brickell Biotech up 23% on results from phase 3 study
07 Oct 2021 //
SEEKINGALPHA
Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A
17 Sep 2021 //
GLOBENEWSWIRE
Brickell to pay Voronoi up to $320M for inhibitors, hires CMO
02 Sep 2021 //
FIERCEBIOTECH
NMPA approves Gloria`s anti-PD-1 drug; Brickell gains rights to DYRK1A inhibitor
01 Sep 2021 //
ENDPTS
Brickell Biotech Announces Second U.S. Phase 3 Study of Sofpironium Bromide Gel
16 Aug 2021 //
GLOBENEWSWIRE
Brickell Second Quarter 2021 Financial Results and Provide a Corporate Update
29 Jul 2021 //
GLOBENEWSWIRE
Brickell Closing of $8.05 Million Bought Deal Offering , Including Full Exercise
22 Jul 2021 //
GLOBENEWSWIRE
Brickell Closing of $8.05 Million Bought Deal Offering , Including Full Exercise
22 Jul 2021 //
GLOBENEWSWIRE
Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021
06 Jul 2021 //
GLOBENEWSWIRE
Brickell Biotech Announces update for Sofpironium Bromide Gel
29 Jun 2021 //
GLOBENEWSWIRE
Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal
27 Apr 2021 //
GLOBENEWSWIRE
Brickell Biotech Reports Results U.S. Phase 3 Open-Label, Long-Term Safety
23 Apr 2021 //
GLOBENEWSWIRE
Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported
16 Apr 2021 //
GLOBENEWSWIRE
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term
16 Apr 2021 //
BIOSPACE
Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study
19 Jan 2021 //
BIOSPACE
Brickell Biotech Doses First Patient in Second U.S. Pivotal Ph3 Study
07 Dec 2020 //
GLOBENEWSWIRE
Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5%
18 Nov 2020 //
GLOBENEWSWIRE
Brickell Announces Initiation of US Ph3 Trial for Sofpironium Bromide Gel
06 Oct 2020 //
GLOBENEWSWIRE
Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan
25 Sep 2020 //
SEEKING ALPHA
Brickell Biotech Announces Issuance of Matter Patent on Sofpironium Bromide
31 Aug 2020 //
BIOSPACE
Brickell Biotech Announces +VE Ph3 Pivotal Study Results for Sofpironium Bromide
15 Jun 2020 //
GLOBENEWSWIRE
Brickell Biotech Announces Late-Breaking Oral Presentation at 2020
04 Mar 2020 //
GLOBENEWSWIRE
